Vilon (20 mg Vial)
Vilon (Lys‑Glu) is a synthetic immunoregulatory dipeptide consisting of lysine and glutamic acid residues. Preclinical research indicates it may enhance immune markers including CD5+ lymphocytes and interleukin‑2 expression in thymic and splenic cell cultures. This educational protocol presents a pulsed subcutaneous approach (5 consecutive days per 4‑week cycle) using a practical dilution for clear insulin‑syringe measurements.
Detailed protocol below.
| Phase / Cycle | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Cycle 1, Day 1 | 67 mcg (0.067 mg) | 1 unit (0.01 mL) |
| Cycle 1, Day 2 | 133 mcg (0.133 mg) | 2 units (0.02 mL) |
| Cycle 1, Day 3 | 200 mcg (0.20 mg) | 3 units (0.03 mL) |
| Cycle 1, Day 4 | 267 mcg (0.267 mg) | 4 units (0.04 mL) |
| Cycle 1, Day 5 | 333 mcg (0.33 mg) | 5 units (0.05 mL) |
| Cycle 2+ (Days 1–5) | 333–667 mcg (0.33–0.67 mg) | 5–10 units (0.05–0.10 mL) |
- •Peptide Vials (Vilon, 20 mg each):
- •Insulin Syringes (U‑100, 30‑ or 50‑unit preferred):
- •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Sevostianova NN et al. (2013)
Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells
View sourceKazakova TB et al. (2002)
In vitro effect of short peptides on expression of interleukin‑2 gene in splenocytes
View sourceGavrisheva NA et al. (2005)
Effect of Vilon peptide on TGF‑β1 and vascular permeability in chronic renal failure
View sourceKniaz’kin IA et al. (2002)
Effect of a peptide Vilon on immune aging (Adv Gerontol)
View sourceAraj SK et al. (2025)
Overview of Epitalon—highly bioactive pineal tetrapeptide with promising properties (Int J Mol Sci)
View sourceChernyak EY et al. (2000)
Synthetic dipeptide Vilon inhibits tumor growth and prolongs life in mice (Dokl Biol Sci)
View sourceAvolio F et al. (2022)
Peptides regulating proliferative activity and inflammatory pathways in THP‑1 macrophages (Int J Mol Sci)
View sourceWong AKC et al. (2024)
Injection techniques to reduce subcutaneous heparin complications (J Adv Nurs)
View sourceMedlinePlus (NIH)
Subcutaneous (SQ) injections: patient information
View sourceMerck KGaA (Millipore Sigma)
Handling and storage guidelines for peptides and proteins
View sourceCDC
Vaccine administration: subcutaneous route (angle/site; no aspiration)
View sourceNCBI Bookshelf
Best practices for injection (asepsis, preparation, and administration)
View source
Educational content adapted from peptidedosages.com. Not medical advice.